Abdelnaseer, M. M., N. M. ElFauomy, E. H. Esmail, M. M. Kamal, and E. H. Elsawy, "Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke.", Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, vol. 26, issue 4, pp. 733-740, 2017 Apr. Abstract

BACKGROUND: Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9-after the acute stage-and clinical recovery.

OBJECTIVE: The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery.

METHODS: The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group.

RESULTS: The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery.

CONCLUSION: Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.

Shehata, H. S., E. H. Esmail, A. Abdelalim, S. El-Jaafary, A. Elmazny, A. Sabbah, and N. M. Shalaby, "Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial.", Journal of pain research, vol. 9, pp. 771-777, 2016. Abstract

BACKGROUND: Chronic migraine is a prevalent disabling disease, with major health-related burden and poor quality of life. Long-term use of preventive medications carries risk of side effects.

OBJECTIVES: The aim of this study was to compare repetitive transcranial magnetic stimulation (rTMS) to botulinum toxin-A (BTX-A) injection as preventive therapies for chronic migraine.

METHODS: A pilot, randomized study was conducted on a small-scale sample of 29 Egyptian patients with chronic migraine, recruited from Kasr Al-Aini teaching hospital outpatient clinic and diagnosed according to ICHD-III (beta version). Patients were randomly assigned into two groups; 15 patients received BTX-A injection following the Phase III Research Evaluating Migraine Prophylaxis Therapy injection paradigm and 14 patients were subjected to 12 rTMS sessions delivered at high frequency (10 Hz) over the left motor cortex (MC, M1). All the patients were requested to have their 1-month headache calendar, and they were subjected to a baseline 25-item (beta version) Henry Ford Hospital Headache Disability Inventory (HDI), Headache Impact Test (HIT-6), and visual analogue scale assessment of headache intensity. The primary efficacy measures were headache frequency and severity; secondary measures were 25-item HDI, HIT-6, and number of acute medications. Follow-up visits were scheduled at weeks 4, 6, 8, 10, and 12 after baseline visit.

RESULTS: A reduction in all outcome measures was achieved in both the groups. However, this improvement was more sustained in the BTX-A group, and both the therapies were well tolerated.

CONCLUSION: BTX-A injection and rTMS have favorable efficacy and safety profiles in chronic migraineurs. rTMS is of comparable efficacy to BTX-A injection in chronic migraine therapy, but with less sustained effect.

Esmail, E., A. Nawito, D. labib, and B. MA, "Focal interictal epileptiform discharges in idiopathic generalized epilepsy.", Neurol Sci., vol. 38, issue 7, pp. 1071-7, 2016.
M, A., E. N, E. EH, K. MM, H. A, S. RM, and E. E, "Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness.", Neurol Sci., vol. 37, issue 1, pp. 117-22, 2016.
M, A., E. N, E. EH, K. MM, H. A, S. RM, and E. E, "Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness.", Neurol Sci., vol. 37, issue 1, pp. 117-22, 2016.
Abdelnaseer, M. M., N. M. ElFauomy, Eman H. Esmail1, M. M. Kamal, and E. H. Elsawy, "Relation of Matrix Metalloproteinase-9 to Size of Infarction and Hemorrhagic Transformation in Acute Ischemic Stroke", Egypt J Neurol Psychiat Neurosurg. , vol. 51, issue 4, pp. 471-476, 2014.
Shehataa, H., M. Tamawya, N. Mohieldina, E. Hassan, and A. Nawetob, "Can repetitive transcranial magnetic stimulation (RTMS) help on-freezers with advanced PD?", World Congress of Neurology, 2013 .
El-Banhawya, I., M. El-Toukhyb, I. Fahmya, N. M. Shalabya, M. A. Nadaa, H. S. Shehataa, and I. Ismaiel, "Role of magnetic resonance spectroscopy in differentiating parkinsonian syndromes of various etiologies", WCN (World Congress of Neurology). abstract Nb.992, 2013 .
El-Tamawy, M. S., H. S. Shehata, N. M. Shalaby, A. Nawito, and E. H. Esmail, "Can Repetitive Transcranial Magnetic Stimulation Help On-Freezers with Parkinson’s Disease?", Journal of the Neurological Sciences , 2013.
El-Kattan, M. M., A. M. Ebraheim, E. Hassan, and E. A. M. Hakim, "Temporal Lobe Epilepsy: Memory Based Cognitive Assessment", Egypt J Neurol Psychiat Neurosurg. , vol. 50, issue 3, pp. 241-247, 2013.
Tourism